SCHEMBL7030353

SCHEMBL7030353

CC(C)[Si](Cl)(C=Cc1ccccc1O)C(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.44
LMNA P02545 2/20 0.44
TRPA1 O75762 1/20 0.44
NFKB1 P19838 2/20 0.43
CDK4 P11802 1/20 0.43
CCND1 P24385 1/20 0.43
JUN P05412 1/20 0.43
NFE2L2 Q16236 1/20 0.43
CA2 P00918 2/20 0.42
CA1 P00915 1/20 0.42
CA4 P22748 1/20 0.42
TRIM24 O15164 1/20 0.39
TRIM33 Q9UPN9 1/20 0.39
ECE2 P0DPD6 2/20 0.39
ABL1 P00519 1/20 0.39
ABCB1 P08183 1/20 0.39
BCR P11274 1/20 0.39
BCHE P06276 1/20 0.39
GUSB P08236 1/20 0.39
MAPK1 P28482 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7030351 1.00 MAPT (0.44) MAPTLMNATRPA1NFKB1CDK4
SCHEMBL2351168 0.80 MAPT (0.46) MAPTLMNATRPA1NFKB1CDK4
SCHEMBL7030075 0.79 MAPT (0.48) MAPTLMNATRPA1NFKB1CDK4
SCHEMBL7030080 0.79 MAPT (0.48) MAPTLMNATRPA1NFKB1CDK4
SCHEMBL7028957 0.79 MAPT (0.44) MAPTLMNATRPA1NFKB1CDK4
SCHEMBL7028954 0.79 MAPT (0.44) MAPTLMNATRPA1NFKB1CDK4
SCHEMBL435159 0.77 ABL1 (0.45) MAPTLMNATRPA1NFKB1CDK4
SCHEMBL435160 0.77 ABL1 (0.45) MAPTLMNATRPA1NFKB1CDK4
SCHEMBL5345372 0.75 TRPA1 (0.52) MAPTLMNATRPA1NFKB1CDK4
SCHEMBL5345374 0.75 TRPA1 (0.52) MAPTLMNATRPA1NFKB1CDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030055297-A1 An alkyl, cycloalkyl, arylalkyl dihydroxy compound useful as intermediates; a cost-effective preparation ABBOTT LABORATORIES 2003-03-20 US disclosed
WO-2002081441-A1 PROCESS FOR THE PREPARATION OF SUBSTITUTED PYRROLIDINE NEURAMINIDASE INHIBITORS ABBOTT LABORATORIES (US) 2002-10-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055297-A1 An alkyl, cycloalkyl, arylalkyl dihydroxy compound useful as intermediates; a cost-effective preparation NEU4, NEU2, NEU1 MAPT 4848/4885LMNA 2961/4885TRPA1 4337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.